Anika Q1 revenue down 10% to $26.2M; lowers FY2025 Adj. EBITDA guidance to -3% to 3%

Anika Therapeutics, Inc.

2025-Q1 EPS reported -$0.34 revenue$26,168,000

Revenue $26.2M, down 10% YoY; OEM channel down 23% to $14.9M, Commercial channel up 18% to $11.3M.
Adjusted net loss from continuing ops $0.9M ($0.06/share); Adjusted EBITDA $0.1M; cash $53.4M, no debt.
Updated FY2025 guidance: OEM revenue $62-65M (down 16-20%); Adj. EBITDA -3% to 3% (prev 8-10%).
Integrity procedures on pace to more than double in 2025; over 300 surgeries in Q1; Regenerative Solutions portfolio up 33% YoY.
Key regulatory milestones: Hyalofast second PMA module filed, MDR approved; Cingal NDA path cleared with FDA feedback.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.